ABIONYX Pharma Announces Its Financial Agenda for the Year 2023
13 Januar 2023 - 07:30AM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies for patients, today announces
its financial agenda for 2023.
Events
Date*
Cash position and activity update for
Q4 2022
Tuesday, February 28, 2023
2022 Full-Year Results
Thursday, April 27, 2023
Cash position and activity update for
Q1 2023
Wednesday, May 17, 2023
Cash position and activity update for
Q2 2023
Thursday, August 17, 2023
2023 Half-Year Results
Thursday, September 28, 2023
Cash position and activity update for
Q3 2023
Thursday, November 16, 2023
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230112005910/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 94
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Feb 2023 bis Mär 2023
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Mär 2022 bis Mär 2023
